

A Novel One Step Real Time RT-PCR Assay for the Detection of Enterovirus

Weston C. Hymas¹ and David R. Hillyard^{1,2}

Institute for Clinical and Experimental Pathology¹, Department of Pathology²,
University of Utah Health Sciences Center, Salt Lake City, Utah.

Introduction

Enteroviruses (EV) are the leading cause of aseptic meningitis in pediatric and adult populations and can be associated with severe disease such as myocarditis, encephalitis, and paralytic poliomyelitis. RT-PCR has rapidly become the diagnostic methodology of choice due to its sensitivity and rapid turn-around-time allowing significant improvement in patient care and management. Most molecular assays target the highly conserved regions within the 5' nontranslated region (NTR) described by Rotbart et al. We describe the development of a novel real time assay that amplifies and detects a conserved region upstream of the Rotbart amplicon utilizing primers and an Eclipse probe. As a further enhancement, an RNA internal control (IC) is integrated into the reaction. The analytical sensitivity was determined and a comparison to the Chemicon Oligodetect Pan-enterovirus kit was made during the 2005 enterovirus season.

Results

Analytical sensitivity was determined using 2-fold serial dilutions of positive control material. The real time assay demonstrated 100% analytical sensitivity compared to the PCR-Chemicon assay (Figure 1 & Table 2).

Twenty-two of the 76 specimens were positive for enterovirus using the PCR-ELISA method, whereas the real-time assay identified only 16 out of these 22. The remaining 54 specimens were negative by both assays (Table 3).

DNA sequencing was performed on the 6 discrepant patient specimens that failed to exhibit a recognizable crossing threshold in the real time assay. Sequencing results indicated the upstream priming region in 5 of the 6 discrepant samples contained one variable nucleotide position with two distinct single nucleotide polymorphisms (SNP). Four discrepant samples contained a T to G SNP. One of the remaining two samples contained at T to A polymorphisms (Figure 2). These SNPs appear to be newly discovered during this study.

Conclusion

This real time assay design containing an RNA internal control demonstrated excellent analytical sensitivity when compared to the PCR-ELISA assay. However, upon testing individual and unique clinical samples it became evident that the clinical sensitivity was substandard due to unidentified polymorphisms underneath a primer. Although the frequency of these SNPs in nature is uncertain, the identification of 6 out of 22 (27%) positive patient specimens in this study suggests that this region may be potentially compromised in a considerable percentage of enterovirus specimens. This discovery lends a warning to all groups using or developing new assays for enterovirus that there may be additional unknown SNPs within the "conserved" 5' NTR and that these tests should be rigorously validated using clinical samples. Future directions for this assay include incorporating modified bases to accommodate the newly described SNPs.

Primers and probes	Sequence	Nucleotide positions ^a
--------------------	----------	-----------------------------------

PCR-ELISA

EV1	5' - CCTCCGCGCCCTGAATGCGGCTAAT - 3'	449-473
EV2	5' - biotin-ATTGTCACCATAAGCAGCCA - 3'	583-602
Probe (Antisense)	5' - GAAACACGGACACCCAAAGTA - 3'	547-567

Real time RT-PCR Assay

EV-F	5' - GA*AGAGA*CTAG*TGA*GCTA - 3'	422-439
EV-R	5' - GTTAGGA*TTAGCCGCATTG - 3'	461-479
Probe	5' - MGB - TCCGGCCCCCTGAATGC - FAM - 3'	451-466

IC - Forward	5' - CCA*TCAAA*GTCGA*GGTGCCTAAAGTG - 3'	1513-1538 ^b
IC - Reverse	5' - ACGAACGCCATGCGGCTACAGGAAGCTC - 3'	1563-1590
IC Probe	5' - MGB - TGTGGTGGTGTAGAGC - PY - 3'	1550-1566

^aCorresponding nucleotide position in Cox B5

^bCorresponding nucleotide position in ms2 Phage

A*, G* = super A base, super G Nanogen/Epoch Biosciences

Table 1. Primers and probes used for the detection of Enterovirus from patient specimens by the 2 assays.




Figure 1. Amplification of 2-fold serial dilutions of positive control material.

Dilution	Real Time C _T	Chemicon OD
1	38.47	> 3.0
2	38.85	2.465
3	39.30	1.353
4	41.57	0.615
5	43.78	0.394
6	44.68	Neg
7	46.74	Neg
8	Neg	Neg

Table 2. Analytical sensitivity comparison between the 2 assays using serial 2-fold dilutions of control material.

	Chemicon +	Chemicon -
Real Time +	16	0
Real Time -	6	54

Table 3. Comparative results of the 76 samples tested in both assays .

Cox A 2	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATAATGGCTGCTATGGTGACAATTA
Cox A 3	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTAAATTTT-TACTGGCTGCTATGGTGACAATTA
Cox A 4	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATGGCTGCTATGGTGACAATTA
Cox A 5	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 6	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATATGGCTGCTATGGTGACAATTA
Cox A 7	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATATGGCTGCTATGGTGACAATTA
Cox A 8	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 9	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATATGGCTGCTATGGTGACAATTA
Cox A 10	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATATGGCTGCTATGGTGACAATTA
Cox A 12	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 13	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTATATGGCTGCTATGGTGACAATTA
Cox A 14	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 15	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 16	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 17	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 18	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 20	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 21	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 22	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox A 24	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox B 1	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox B 2	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox B 3	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox B 4	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox B 5	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Cox B 6	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 1	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 2	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 3	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 4	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 5	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 6	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 7	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 9	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 11	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Echo 25	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Enter68	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Enter69	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Enter70	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Enter71	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Polio 1	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Polio 2	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA
Polio 3	GGTCCGAAGAGCCTATTGAGCTAAGTGGTAGTCCTCCGGCCCCCTGAATGGCGCTAATCTAACTGCGGAGCAATACCCCTTAATCCAAAGGGCAGTGTCTCGTAACGGTAACCTGCGACGGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTATTCTTTACACTGGCTGCTATGGTGACAATTA

EV1	CCTCCGGCCCCCTGAATGGCGGCTAAT→	ATTGAACCCACAGGCACAAAG	←ACCGACGAATACCACTGTGTA
EV Probe(ELISA) antisense strand			
EV2			
EV-F	GAAGAGACTAGTGAGCTA→		
Probe		TCCGGCCCCCTGAATGC	
EV-R	←CTTAGCGCCGATTAGGATTG		



Figure 2. Electropherograms showing newly identified polymorphisms. The uppermost electropherogram is the wild type.

Research: Pre-Submission Approval Form

Approval is required **before information is presented outside of ARUP and enters the public domain** to ensure that HIPAA and IRB protocols have been followed. Please ensure that this document is signed and appropriate documents are attached before submitting any information for publication/presentation outside of ARUP.

☐ Attach copy of (please indicate) manuscript, poster, abstract, or other presentation

Presentation/Poster presented at (specify meeting or conference): _____

ARUP Cited: Yes ☐ No ☐ If no, state reason: _____

☐ Global IRB #7275 applies, and PRCS-0020, *Internal Sample Request: De-Identification of Samples* has been followed **OR**

☐ Independent Institutional Review Board (IRB) approval, IRB# _____
Attach copy of approved IRB protocol.

OR

☐ IRB is not applicable. Please explain: _____

Scientist/Researcher: _____ Date: _____
Signature

Approval Signatures and Dates:

Medical Director: _____ Date: _____

R&D Group Manager or
ARUP Privacy Officer: _____ Date: _____

CONFIDENTIAL: This material is prepared pursuant to Utah Code Annotated, 26-25-1, et seq., for the purpose of evaluating health care rendered by hospitals or physicians and it NOT PART of the medical record.